Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression
β Scribed by Andrew F. Leuchter; Melinda Morgan; Ian A. Cook; Jennifer Dunkin; Michelle Abrams; Elise Witte
- Publisher
- Springer
- Year
- 2004
- Tongue
- English
- Weight
- 162 KB
- Volume
- 177
- Category
- Article
- ISSN
- 0033-3158
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The use of a placebo run-in phase, in which placebo responders are withdrawn from a study before random assignment to treatment condition, has been criticized as favoring the active treatment in clinical trials. We compared the effect size of randomized, placebo-controlled clinical trials (in the tr
## Abstract ## Objective To examine the safety and tolerability of the antidepressant duloxetine across multiple studies for major depressive disorder (MDD). ## Method Safety data were integrated from the acute phases of eight doubleβblind, placeboβcontrolled trials in which patients were random
## Abstract A randomized clinical trial was undertaken to investigate the relative efficacy of rationalβemotive behavior therapy (REBT), cognitive therapy (CT), and pharmacotherapy in the treatment of 170 outpatients with nonpsychotic major depressive disorder. The patients were randomly assigned t